![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1635891
ÇåÆÃÅϺ´ Ä¡·á ½ÃÀå º¸°í¼ : À¯Çüº°, ¾à¹° À¯Çüº°, ¿¬·Éº°, À¯Åë ä³Îº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)Huntington¢¥s Disease Treatment Market Report by Type, Drug Type, Age, Distribution Channel, End User, and Region 2025-2033 |
ÇåÆÃÅϺ´ Ä¡·á ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 5¾ï 7,890¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 24¾ï 4,300¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025³âºÎÅÍ 2033³â±îÁö 17.4%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÇåÆÃÅϺ´ÀÇ ÁÖ¿ä µ¿ÇâÀÇ Áõ°¡, ÷´Ü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Çõ½ÅÀûÀÎ Ä¡·á Á¢±Ù¹ýÀÇ ÃÖ±Ù °³¹ßÀº ½ÃÀåÀ» ÁÖµµÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.
ÇåÆÃÅϺ´Àº ³ú ½Å°æ¼¼Æ÷ÀÇ ÆÄ±«°¡ ÁøÇàµÇ´Â Ä¡¸íÀûÀÎ ½Å°æ ÅðÇ༺ ÁúȯÀÔ´Ï´Ù. ÇåÆÃÅϺ´ÀÇ Áõ»óÀ¸·Î´Â ºÒ¼öÀÇÀû ¿îµ¿, ±Ù·ÂÀå¾Ö, Á¤¸® ¹× ÁýÁß·Â Àå¾Ö, ÀǽÄÀå¾Ö, ºÒ¸éÁõ, »çȸÀû ÀºµÐ µî ´Ù¾çÇÑ ¿îµ¿Àå¾Ö, Á¤½ÅÀå¾Ö, ÀÎÁöÀå¾Ö µîÀÌ ÀÖ½À´Ï´Ù. ÇåÆÃÅϺ´ Ä¡·á¿¡´Â Ç×Á¤½Åº´¾à, Ç׿ì¿ïÁ¦, ÇׯÄŲ½¼º´¾à, Ç׿ì¿ïÁ¦, ±âºÐ¾ÈÁ¤Á¦ µî ´Ù¾çÇÑ ¾à¹°ÀÌ »ç¿ëµË´Ï´Ù. Ä¡·á °úÁ¤¿¡´Â ¾ð¾îÄ¡·á, ÀÛ¾÷Ä¡·á, ¹°¸®Ä¡·á, ½É¸®Ä¡·á µî ´Ù¾çÇÑ Ä¡·áµµ Æ÷ÇԵ˴ϴÙ. ÇåÆÃÅϺ´ Ä¡·á´Â ¿îµ¿Àå¾Ö¿Í Á¤½ÅÀå¾ÖÀÇ Áõ»óÀ» ÃÖ¼ÒÈÇϰí, ȯÀÚ°¡ ´Ü±â°£¿¡ »õ·Î¿î ´É·Â¿¡ ÀûÀÀÇÒ ¼ö ÀÖµµ·Ï µ½°í, ´ëóÀü·«À» °³¹ßÇϵµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ ÀÏ»óÀûÀÎ ÀÛ¾÷°ú ¸»Çϱâ, ÀÚ¼¼¿Í ±ÕÇü À¯Áö, »îÀÇ Áú Çâ»ó¿¡µµ µµ¿òÀÌ µË´Ï´Ù.
Àü ¼¼°èÀûÀ¸·Î ÇåÆÃÅϺ´ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÇåÆÃÅϺ´ Ä¡·á´Â ºñÀÚ¹ßÀû ¿îµ¿ ¹× ¿òÁ÷ÀÓ ¾ïÁ¦, ¹«µµº´ Ä¡·á, Æø·ÂÀû Æø¹ß ¹× ÈïºÐ ¾ïÁ¦, ±Ù·Â, À¯¿¬¼º, ±ÕÇü, ÇùÀÀ·Â °È µî¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ±× °á°ú »îÀÇ ÁúÀÌ Çâ»óµÇ°í ½Ä»ç, ÀÇ»ç¼ÒÅë, º¸Çà°ú °°Àº ÀÏ»óÀûÀÎ ·çƾ ÀÛ¾÷À» ¼öÇàÇϴ ȯÀÚÀÇ ´É·ÂÀÌ °ÈµË´Ï´Ù. °ÈµË´Ï´Ù. ¶ÇÇÑ, ÇåÆÃÅϺ´ÀÇ ¿îµ¿, ÀÎÁö, Á¤½Å Áõ»óÀ» Á¶ÀýÇϴ ÷´Ü ¾à¹°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ÇåÆÃÅϺ´°ú ±× ±Ùº»ÀûÀÎ ¿øÀο¡ ´ëÇÑ ÀÌÇØ°¡ ±í¾îÁö°í, »õ·Î¿î Áúº´ º¯Çü ¾à¹°ÀÇ °³¹ßÀÌ ºü¸£°Ô ÁøÇàµÇ°í ÀÖ´Â °Íµµ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¯ÀÌÇü ÇåÆÃÅϺ´(mTT) »ý»ê ¼öÁØÀ» ³·ÃãÀ¸·Î½á ÇåÆÃÅϺ´ÀÇ ¼ºÀåÀ» ¾ïÁ¦ÇÏ´Â Çõ½ÅÀûÀÎ Ä¡·á Á¢±Ù¹ýÀÇ ÃÖ±Ù µ¿ÇâÀº ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, ÇåÆÃÅÏ(HTT) ¸Þ½ÅÀú ¸®º¸ÇÙ»ê(mRNA)°ú ÁßÃ߽Űæ°è(CNS) Àüü¿¡¼ ÇØ´ç ´Ü¹éÁúÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ¾ÈƼ¼¾½º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå(ASO)¸¦ »ç¿ëÇÏ´Â ¾ÈƼ¼¾½º ±â¼úÀÇ µµÀÔÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿©·¯ Á¤ºÎÀÇ ½Å¾à °³¹ß ÃËÁø¿¡ ´ëÇÑ ³ë·ÂÀÌ È°¹ßÇØÁö°í ÀÖ´Â °Íµµ ½ÃÀå °³Ã´¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ±× ¿Ü, ÇåÆÃÅϺ´¿¡ ´ëÇÑ ´ëÁßÀÇ ÀÎ½Ä Áõ°¡, ÇコÄÉ¾î »ê¾÷ÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå, ¿¬±¸°³¹ß(R&D) Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ³ë·É Àα¸ Áõ°¡, ÀûÀÀÁõ ¿Ü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global Huntington's disease treatment market size reached USD 578.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,443 Million by 2033, exhibiting a growth rate (CAGR) of 17.4% during 2025-2033. The rising incidences of Huntington's disease, the increasing demand for advanced drugs for the disease treatment, and recent development of innovative therapeutic approaches represent some of the key factors driving the market.
Huntington's disease refers to a fatal neurodegenerative disorder that causes the progressive breakdown of nerve cells in the brain. Its symptoms include various movement, psychiatric, and cognitive impairments, such as involuntary jerking, muscle problems, difficulty in organizing and focusing, lack of awareness, insomnia, and social withdrawal. Huntington's disease treatment involves the application of various drugs, such as antipsychotics, antidepressants, antiparkinsonians, and mood-stabilizing drugs. The treatment process also includes various therapies, such as speech, occupational, physical, and psychotherapy. Huntington's disease treatment helps in minimizing the symptoms of movement and psychiatric disorders, assists patients in adapting to new abilities in a shorter time, and develops coping strategies. It also aids in improving everyday tasks, speech, maintaining posture and balance, and enhancing the quality of life.
The rising incidence of Huntington's disease across the globe is one of the primary factors driving the market growth. Huntington's disease treatment is widely used to suppress involuntary jerking and writhing movement, treat chorea, reduce violent outbursts and agitation, and enhance strength, flexibility, balance, and coordination, which, in turn, improves the quality of life and enhances the patient's ability to carry out daily routine tasks, such as eating, communications, and walking. Furthermore, the increasing demand for advanced drugs to control the motor, cognitive, and psychiatric symptoms associated with Huntington's disease is providing an impetus to the market growth. In line with this, the rapid development of new disease-modifying drugs owing to the improved understanding of the disease, and its underlying causes are acting as another growth-inducing factor. Additionally, the recent development of the innovative therapeutic approach that deters the growth of Huntington's disease by reducing mutant huntingtin (mTT) production levels is positively influencing the market. Apart from this, the introduction of antisense technology that uses antisense oligonucleotides (ASOs) to target huntingtin (HTT) messenger ribonucleic acid (mRNA) and its protein throughout the central nervous system (CNS) is propelling the market growth. Moreover, increasing initiatives by several governments to promote the development of novel drugs are favoring the market growth. Other factors, including rising awareness among the masses regarding Huntington's disease, significant growth in the healthcare industry, increasing investment in research and development (R&D) activities, rising geriatric population, and escalating demand for off-label medications, are anticipated to drive the market growth.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.